Related Experiment Video
Updated: Aug 6, 2026
07:13
Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
Published on: January 6, 2015
Perfluorochemical elimination from the lungs: effect of initial dose
C M Weis1, W W Fox, C M Philips
1Department of Newborn Pediatrics, Pennsylvania Hospital, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Pediatric Pulmonology
|October 3, 2000
Summary
Perfluorochemical (PFC) evaporative loss from the lungs depends on the initial dose size, not just saturation levels. Understanding this relationship is crucial for optimizing PFC application and replacement dosing in liquid ventilation strategies.
Area of Science:
- Biomedical Engineering
- Respiratory Physiology
- Pharmacokinetics
Background:
- Liquid-assisted ventilation using perfluorochemicals (PFCs) shows promise for respiratory diseases.
- Current guidelines for PFC dosing and replacement are not well-defined.
- PFC evaporation from the lungs is influenced by ventilation and patient positioning.
Purpose of the Study:
- To investigate the relationship between initial perfluorochemical (PFC) dose and its evaporative loss over time.
- To determine if PFC evaporative loss is predictable by saturation levels.
- To inform optimal dosing strategies for PFCs in liquid ventilation.
Main Methods:
- Juvenile rabbits (n=18) received varying initial doses of perflubron (2, 6, 12, 17 mL/kg).
- Ventilation strategy and animal position were kept constant.
- A thermal detector measured PFC in expired gas to calculate loss rate and residual volume.
Main Results:
- A significant interaction between dose, time, and dose-time was observed for PFC evaporative loss.
- Evaporative loss rate diminished earlier with lower initial PFC doses.
- The percentage of volume lost to evaporation was inversely related to the initial dose and not predictable by saturation.
Conclusions:
- Initial perfluorochemical (PFC) dose size significantly impacts evaporative loss over time.
- Evaporative loss rates are dose-dependent and not solely predictable by PFC saturation.
- Consideration of dose-dependent evaporative loss is essential for optimizing PFC therapy and replacement dosing.
More Related Videos
Related Concept Videos
01:23Drug Elimination: Non-Renal Routes
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
01:26Enhanced Elimination of Poison
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
01:12First Pass Effect
Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
01:24Factors Influencing Drug Absorption: Presystemic Elimination
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
01:18Drug Elimination: Overview
Drug elimination involves many complex processes and does not necessarily differentiate between distribution and elimination. It is divided into two primary components: excretion and biotransformation.
Excretion refers to removing a drug from the body, either in its unchanged form or as its metabolites. Nonvolatile and polar drugs are primarily excreted through the kidneys, with other pathways including bile, sweat, saliva, and milk. Volatile drugs such as anesthetic gases are excreted via the...
Excretion refers to removing a drug from the body, either in its unchanged form or as its metabolites. Nonvolatile and polar drugs are primarily excreted through the kidneys, with other pathways including bile, sweat, saliva, and milk. Volatile drugs such as anesthetic gases are excreted via the...